Roche Reports Positive Phase III Data for GAZYVA/GAZYVARO in Primary Membranous Nephropathy
Roche has reported highly encouraging results from the Phase III MAJESTY study, which evaluated the efficacy and safety of GAZYVA/GAZYVARO (obinutuzumab) in adults suffering from primary membranous nephropathy (PMN). PMN is a rare but debilitating autoimmune kidney disease that can lead to irreversible organ damage if not effectively managed. The study successfully met its primary endpoint, demonstrating that a significantly higher proportion of patients treated with GAZYVA/GAZYVARO achieved complete remission at the two-year mark (104 weeks) compared to those receiving tacr...